Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Market Cap: 440.4B GBX

EV/EBITDA
Enterprise Value to EBITDA

3 846.3
Current
3 846.3
Median
13
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
3 846.3
=
Enterprise Value
440.8B GBX
/
EBITDA
114.6m GBP
All Countries
Close
Market Cap EV/EBITDA
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Eli Lilly and Co
NYSE:LLY
993.4B USD 36.2
US
Johnson & Johnson
NYSE:JNJ
508.5B USD 16.5
CH
Roche Holding AG
SIX:ROG
256.1B CHF 11.6
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP 108.1
CH
Novartis AG
SIX:NOVN
206.4B CHF 11.4
US
Merck & Co Inc
NYSE:MRK
243.7B USD 9.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.5
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
142.5B USD 7.4
FR
Sanofi SA
PAR:SAN
98.7B EUR 6.5
EBITDA Growth EV/EBITDA to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average EV/EBITDA: 399.4
3 846.3
36%
106.8
US
Eli Lilly and Co
NYSE:LLY
36.2
33%
1.1
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
FR
Sanofi SA
PAR:SAN
6.5
8%
0.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
hidden